Drug Trial Radar · NCT06878066
Thrombolysis in Factor Xa-inhibitors Trial
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 14, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2037
Sponsor
- Lead sponsor
- Guri HagbergAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Klinbeforsk; Clinical Trial Unit (CTU), Oslo University Hospital
- First posted
- Mar 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours. This is because doctors worry that IVT might cause dangerous bleeding in the brain. However, new research suggests that IVT might be safe for these patients. Some studies even show that stroke patients on FXa inhibitors who receive IVT do not have a higher risk of brain bleeding than other stroke patients. But because these studies were not designed as full medical trials, doctors still avoid IVT for this group. The SIFT trial will compare two groups of stroke patients who take FXa inhibitors: One group will receive IVT to see if it helps them recover better. One group will not receive IVT, which is the current standard. Doctors will check if IVT helps with recovery and if it causes any serious bleeding. If IVT is found to be safe and effective, this study could change stroke treatment guidelines and help more patients get life-saving care. Right now, some guidelines say that stroke patients on FXa inhibitors should have a blood test before getting IVT, to measure how much of the drug is in their system. But these tests are not available in most hospitals, and waiting for results could delay important treatment. The SIFT trial will not require this test before giving IVT. More and more people use FXa inhibitors to prevent strokes, but right now, they are being denied IVT based on old rules. If this study proves that IVT is safe for them, it could help doctors give better care to thousands of stroke patients.
Conditions
- Stroke
- Stroke (in Patients With Atrial Fibrillation)
- Ischemic Stroke
- Acute Ischemic Stroke
- Anticoagulant Therapy
- Factor Xa Inhibitor
- Intracranial Hemorrhages
- Hemorrhagic Transformation Due to Acute Stroke
- Bleeding in the Brain
Interventions
thrombolysis therapyDrug
All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early neurological improvement (ENI)Time frame: 24 hours (22-36 h).
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Dept. of Neurology, Aalborg Universitetshospital
Aalborg, Aalborg, Denmark · Recruiting
Dept of Neurology Aarhus University Hospital
Aarhus, Aarhus N, Denmark · Recruiting
Dept of Medicine, Helse More and Romsdal Health Trust, Aalesund Hospital
Ålesund, Norway · Recruiting
Dept of Medicine, Haraldsplass deaconal Hospital
Bergen, Norway · Recruiting
Dept. Of Neurology, Haukeland University Hopsital
Bergen, Norway · Recruiting
Dept of Neurology, Drammen Hospital Trust
Drammen, Norway · Recruiting
Dept of Neurology, Ostfold Hospital Trust, Kalnes
Grålum, Norway · Recruiting
Dept of Neurology, Hospital of Southern Norway, SSHF
Kristiansand, Norway · Recruiting
Dept of Neurology, Innlandet Hospital Trust, Lillehammer
Lillehammer, Norway · Recruiting
Dept. of Neurology, Oslo University Hospital
Oslo, Norway · Recruiting
Dept of Neurology, Stavanger University Hospital
Stavanger, Norway · Recruiting
Dept of Neurology, Vesfold Hospital Trust, Tonsberg
Tønsberg, Norway · Recruiting
Dept. of Neurology, Tromso University Hospital
Tromsø, Norway · Recruiting
Dept. Of Medicine, St.Olav Hospital, Trondheim
Trondheim, Norway · Recruiting
Dept. of Medicine, Baerum Hospital
Baerum, Gjettum, Norway · Recruiting
Dept of Neurology Danderyd Hospital
Stockholm, Danderyd, Sweden · Recruiting
Dept of Neurology , Lund University Hospital
Lund, Lund, Sweden · Recruiting
Dept of Neurology, Stroke Unit Skåne University Hospital
Malmö, Malmö, Sweden · Recruiting
Dept of Neurology, Karolinska University Hospital
Stockholm, Stockholm County, Sweden · Recruiting
Dept of Neurology Norrland University Hospital
Umeå, Umeå, Sweden · Recruiting
Dept of Neurology, Uppsala University Hospital
Uppsala, Uppsala County, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.